All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the EHA2021 Virtual Congress, the MPN Hub spoke with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Does fedratinib provide a survival benefit in patients with myelofibrosis (MF)?
JAKARTA trials: Does fedratinib provide a survival benefit in patients with MF?
Harrison discusses the JAKARTA phase III trial results, which led to the approval of fedratinib, a JAK2 inhibitor, as a first- and second-line treatment for patients with MF.
Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?
The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San Antonio, US, during the 61st American Society of...
Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis
Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of myelofibrosis (MF) and related myeloproliferative...
Subscribe to get the best content related to MPN delivered to your inbox